Xtl Biopharmaceuticals (XTLB) Assets Average (2009 - 2025)

Xtl Biopharmaceuticals (XTLB) has reported Assets Average for 17 consecutive years, with $440000.0 the latest figure, recorded in Q4 2025.

• Quarterly Assets Average fell 95.06% year-over-year to $440000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $440000.0 (down 95.06% YoY) and the FY2025 annual result came in at $4.4 million, down 20.59% from the prior year.
• Assets Average slipped to $440000.0 in Q4 2025 per XTLB's latest filing, from $4.6 million in the prior quarter.
• Over the last five years, Assets Average for XTLB reached as high as $8.9 million in Q4 2024 and fell as low as $440000.0 in Q4 2025.
• A 5-year average of $4.9 million and a median of $5.0 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2024 — Assets Average jumped 250.36% — and 2025, when it plunged 95.06%.
• Year by year, Assets Average stood at $6.7 million in 2021, then sank by 32.58% to $4.5 million in 2022, then tumbled by 43.97% to $2.5 million in 2023, then soared by 250.36% to $8.9 million in 2024, then tumbled by 95.06% to $440000.0 in 2025.
• According to Business Quant data, Assets Average over the past three periods registered $440000.0, $4.6 million, and $8.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.